Key facts
- Houdini Bio’s last known valuation is $3.9M (Feb 2026).
- It has raised $930K; the latest was Early Stage VC ($930K) in Feb 2026.
- Notable investors include Future Planet Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Houdini Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Houdini Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Houdini Bio
Developer of computational synthetic biology technologies designed to redesign DNA for the advancement of genetic medicines. The company utilizes computational platforms to engineer DNA for durable and scalable performance, enabling biotechnology and pharmaceutical partners to improve the overall production and therapeutic efficacy of next-generation genetic therapeutics.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2025
- Employees
- 2
- Website
- houdinibio.com/
- Ownership
- Privately Held (backing)
Houdini Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Houdini Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Houdini Bio in its N-PORT filings yet. We sweep new filings monthly.